Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Frequently asked questions
What sector does Vor Biopharma Inc (VOR) operate in?
Vor Biopharma Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Vor Biopharma Inc (VOR) current stock price?
As of the latest data, Vor Biopharma Inc stock price is $18.33, with a previous close of $18.26. Vor Biopharma Inc gained $0.07 in the last trading session, representing a 0.38% increase.
What is Vor Biopharma Inc (VOR) current market capitalization?
Vor Biopharma Inc market cap is approximately 993.23 million.
What is Vor Biopharma Inc (VOR) Earnings Per Share (EPS)?
The trailing EPS is $180.37, and the forward EPS is -$3.67.
What is Vor Biopharma Inc (VOR) Price-to-Earnings (P/E) ratio?
Vor Biopharma Inc current P/E ratio is 0.1.
What is Vor Biopharma Inc (VOR) EBITDA?
Vor Biopharma Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -47.82 million.
Does Vor Biopharma Inc (VOR) pay dividends?
No. Vor Biopharma Inc does not pay a dividend.
When is Vor Biopharma Inc (VOR) next earnings report?
Vor Biopharma Inc is expected to release its next earnings report on September 30, 2026.
What is Vor Biopharma Inc (VOR) beta (volatility) score?
Vor Biopharma Inc has a beta of 1.783, suggesting it is more volatile than the market.
